Prescribing information

 

                _

Key efficacy data for ILARIS® (canakinumab) in the treatment of FMF, HIDS/MKD, TRAPS and CAPS.

ILARIS can help FMF, HIDS/MKD and TRAPS patients to achieve a rapid and complete response1

At Week 16, significantly more patients receiving ILARIS had achieved the primary endpoint of a complete response* vs placebo.1

Graph showing the proportion of crFMF, HIDS/MKD and TRAPS patients who met the primary outcome at week 16

Adapted from De Benedetti et al. 2018.1

In an exploratory analysis, including those who received a blinded dose increase of ILARIS to 300 mg every 4 weeks before Day 29, significantly more patients achieved a complete response* with ILARIS than with placebo at Week 16.1

 

Proportion of patients who had a complete response* at Week 16, including those who received a blinded dose increase of ILARIS to 300 mg every 4 weeks

Graph showing the proportion of crFMF, HIDS/MKD and TRAPS patients, including those who received a blinded dose increase, who had a complete response at week 16

Adapted from Supplement to De Benedetti et al. 2018.1

 

Study design: CLUSTER study1

A randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of ILARIS in patients with crFMF (n=63), HIDS/MKD (n=72) and TRAPS (n=46). The trial consisted of one cohort per disease. Each cohort followed the same study design:

Epoch 1 (screening)

12-week screening period to confirm study eligibility; patients entered Epoch 2 when they experienced a flare (PGA score ≥2 and CRP >10 mg/L).

Epoch 2 (Weeks 0–16; double-blind)

Patients received 150 mg (or 2 mg/kg) SC of ILARIS or placebo every 4 weeks. All patients were eligible for a blinded dose increase (to ILARIS 300 mg SC) if they had a persistent baseline flare between Days 8 and 14 (PGA score ≥2, or CRP >10 mg/L with <40% reduction from baseline) or a lack of resolution at Day 15 (resolution was defined as a PGA score <2 plus a CRP ≤10 mg/L or a reduction by ≥70% from baseline). After Day 29, patients were eligible for an open-label increase in the dose if they had a flare (PGA score ≥2 and CRP ≥30 mg/L).

Epoch 3

A randomised withdrawal and open-label period of 24 weeks.

Epoch 4

72-week open-label treatment extension period for patients treated with ILARIS.

 

ILARIS can help CAPS patients to achieve a rapid, complete and sustained response§2

Proportion of patients who did not have a flare in the 24-week ILARIS withdrawal phase¶2


Graph showing the proportion of CAPS patients who achieved sustained response in the 24-week withdrawal phase

In the 24-week ILARIS withdrawal phase, 100% of patients receiving ILARIS remained in remission compared with only 19% of patients receiving placebo (p<0.001).2

The primary endpoint was the proportion of patients with a relapse of CAPS during treatment with ILARIS, as compared with placebo, in the withdrawal phase. Remission describes patients who did not have a flare in this phase.¶2


 

Proportion of patients who achieved a complete response in the initial open-label phase§2


Graph showing the proportion of CAPS patients who achieved complete response with a single dose of ILARIS

In the initial open-label phase, 97% of patients achieved complete response§ with a single dose (150 mg); most (n=33/35) achieved this within 15 days.2


 

ILARIS can help CAPS patients to achieve long-term remission3

In a 2-year, open-label study
of 166 CAPS patients treated
with ILARIS:3

Dial showing the proportion of patients maintained on ILARIS who were relapse free

of patients (n=141) maintained on ILARIS** were relapse free.††

In a 152-week, open-label extension study of 17 CAPS patients treated with ILARIS:4

Dial showing the proportion of patients treated with ILARIS who achieved a complete response within 72 weeks

of patients (n=17) achieved a complete response within 72 weeks, and no new relapses‡‡ occurred after Week 96.

 

Study design: Lachmann et al. 20092 

A multicentre, randomised, double-blind, placebo-controlled study of ILARIS for the treatment of CAPS. Eligible patients (aged 4–75 years, weighing 15–100 kg) had CAPS associated with an NLRP3 mutation and required treatment (n=35). Previous treatment with anakinra, rilonacept or ILARIS was permitted if treatment had been discontinued and the patient’s disease had relapsed. The study consisted of three parts:

Part 1

An open-label treatment period in which a single dose of ILARIS was administered. Response was assessed during the following 8 weeks.

Part 2

A double-blind withdrawal period, in which patients who had a sustained complete response in part 1 were randomly assigned to receive either ILARIS or placebo every 8 weeks for up to 24 weeks.

Part 3

At the end of part 2 or at the time of relapse, whichever occurred first, patients immediately entered the open-label part 3 of the study, in which they received ILARIS every 8 weeks for a minimum of 16 weeks, for a total study duration of 48 weeks.

The primary outcome measure was the proportion of patients with a relapse of CAPS during treatment with ILARIS, as compared with placebo, in part 2. Secondary outcome measures included the proportion of patients with a complete response in part 1, values of inflammatory markers, global assessments by physicians and patients, and safety and tolerability.  

 

Study design: Kuemmerle-Deschner et al. 20113

An open-label, phase III study of ILARIS for the treatment of CAPS. Eligible CAPS patients were aged 3 years or older and were either ILARIS-naïve (n=109) or had been pre-treated with ILARIS in a previous study (n=57). Patients received subcutaneous ILARIS 150 mg or weight-based 2 mg/kg (body weight ≤40 kg) every 8 weeks for up to 2 years. In the case of residual symptoms, patients were maintained on a more intense dosing regimen (increased dose of SC ILARIS up to 600 mg or 8 mg/kg [body weight ≤40 kg]) and/or increased dosing frequency. Assessment of complete response and relapse included ratings for disease activity, skin rash and CRP and/or SAA.

 

Study design: Brogan et al. 20194 

A 56-week, multicentre, open-label, phase III core study of ILARIS for the treatment of CAPS. Patients who completed the core study entered the long-term extension study, with a minimum treatment duration of 6 months and a maximum treatment duration of 24 months, until 152 weeks. Eligible CAPS patients were aged 28 days to 60 months, had confirmed NLRP3 mutations and weighed ≥2.5 kg. Previous treatment with the anti-IL-1 agents anakinra or rilonacept was permitted provided these were discontinued prior to the baseline visit and the patient demonstrated active disease prior to enrolment. Patients received subcutaneous ILARIS 2 mg/kg every 8 weeks for the entire study period (including the core and extension studies). Patients in whom a complete response was not achieved after the first dose of ILARIS, and those who experienced a relapse before the next scheduled dose, were eligible for a stepwise dose up-titration (4 to 6 to 8 mg/kg). The main objective of the core study was to assess the efficacy of ILARIS with respect to treatment response. The extension study assessed the long-term efficacy of ILARIS with respect to relapse in patients who completed the core study.

 

 

*Complete response was defined as resolution of the baseline flare at Day 15 (PGA score <2 plus CRP ≤10 mg/L or a reduction by ≥70% from baseline) and no new flare (PGA score ≥2 and CRP ≥30 mg/L) up to Week 16.1
2 mg/kg for patients weighing ≤40 kg.1
For some patients in the CLUSTER study, the timing of up-titration of ILARIS dose or the frequency of ILARIS administration differed from the recommendations of the Summary of Product Characteristics (SmPC). Please refer to the Prescribing Information or the ILARIS SmPC for information on posology.
§Complete response was defined as composite of PGA of autoinflammatory disease activity, and assessment of no or minimal skin disease, and CRP or SAA values <10 mg/L. PGA of disease activity was based on a composite of the following symptoms: urticarial skin rash, arthralgia, myalgia, headache/migraine, conjunctivitis and fatigue/malaise.2
Remission was defined as no disease relapse/flare (CRP and/or SAA value >30 mg/L and either a score of mild or worse for disease activity or a score of minimal or worse for disease activity and skin disease).2
**Patients received ILARIS 150 mg every 8 weeks; median treatment duration was 414 days.3
††
Relapse was defined as a value for either CRP or SAA of more than 30 mg/L, accompanied by a physician’s assessment of global disease activity that was greater than minimal or that was minimal and accompanied by a rash that was assessed as more than minimal.2,3
‡‡
Relapse was defined for complete responders based on clinical features (PGA greater than “minimal” or PGA greater than or equal to “minimal” and assessment of skin disease greater than “minimal”) and serologic features (serum CRP >30 mg/L or SAA >30 mg/L).4

CAPS, cryopyrin-associated periodic syndromes; CRP, c-reactive protein; crFMF, colchicine-resistant familial Mediterranean fever; FMF, familial Mediterranean fever; HIDS, hyperimmunoglobulin D syndrome; IL, interleukin; MKD, mevalonate kinase deficiency; NLRP3, NLR family pyrin domain containing 3; PGA, patient global assessment; SAA, serum amyloid; SC, subcutaneous; TRAPS, tumour necrosis factor receptor-associated periodic syndrome; q4w, every 4 weeks.

Indications

ILARIS is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older:

  • CAPS, including:
    • Muckle-Wells syndrome (MWS)
    • Neonatal-onset multisystem inflammatory disease (NOMID)/chronic infantile neurological, cutaneous, articular syndrome (CINCA)
    • Severe forms of familial cold autoinflammatory syndrome (FCAS)/familial cold urticaria (FCU) presenting with signs and symptoms beyond cold-induced urticarial skin rash
  • TRAPS
  • HIDS/MKD
  • FMF
    • ILARIS should be given in combination with colchicine, if appropriate.

References

  1. De Benedetti F et al. N Engl J Med 2018;378(20):1908–1919.
  2. Lachmann HJ et al. N Engl J Med 2009;360(23):2416–2425.
  3. Kuemmerle-Deschner JB et al. Ann Rheum Dis 2011;70(12):2095–2102.
  4. Brogan PA et al. Arthritis Rheumatol 2019;71(11):1955–1963.
Rate this content: 
No votes yet
UK | November 2021 | 160446
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]